- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Bill would Expand Prompt Medicaid Reimbursement to All Providers
A new bill introduced in the U.S. House of Representatives would require Medicaid to reimburse all providers, including hospitals, nursing facilities, and community health centers, in a timely manner.
As of now, only physicians are guaranteed prompt Medicaid payment. But under the Fair Pay to Medicaid Providers Act proposed by Reps. Brian Bilbray (R-Calif.) and Anna G. Eshoo (D-Calif.), states would have to pay 90 percent of Medicaid claims to all providers within 30 days of receiving the claims, and 99 percent of claims within 90 days.
The bipartisan bill has been referred to the Committee on Energy & Commerce, CardiovascularBusiness notes.
Read the full article at: http://tinyurl.com/c5e89am
Source: Fierce Healthcare
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Overcoming CAR T Manufacturing Failure in LBCL
March 21st 2025Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More
